Earnings call transcript: Alleima AB sees stock dip amid Q2 2025 earnings

Alleima AB reported Q2 2025 adjusted EPS of SEK 1.35 and revenue just under SEK 4.8 billion, both missing analyst forecasts of SEK 1.65 and SEK 5.02 billion respectively, which prompted a 10.95% stock price decline. The company attributed the organic revenue decline of 4% to weakened demand in Europe and North America, alongside broader geopolitical uncertainties. Despite these challenges, Alleima highlighted strong performance in its medical segment and maintains a robust financial position, though it anticipates a seasonally weaker Q3 2025 due to maintenance stops, currency headwinds, and potential cost under-absorption.

Analysis

Alleima AB's second-quarter 2025 results revealed a significant miss on both top and bottom lines, triggering a 10.95% decline in its stock price. The company reported an adjusted EPS of SEK 1.35 against a forecast of SEK 1.65, with revenues just under SEK 4.8 billion falling short of the expected SEK 5.02 billion. This underperformance was driven by a 4% organic revenue decline, stemming from weakened demand in European and North American industrial and chemical markets, coupled with customer investment hesitancy attributed to geopolitical tensions and trade policy uncertainty. Despite these macroeconomic headwinds, the company demonstrated pockets of strength, particularly with strong momentum and a book-to-bill ratio above one in its Medical segment, and maintained a solid backlog in the key Oil & Gas and Nuclear segments. Profitability was notably impacted by a SEK 150 million negative currency headwind, which compressed the adjusted EBIT margin to 9.5%; excluding this effect, the underlying margin was a more resilient 11.4%. However, operational challenges were evident, with the Strip division's performance highlighted as being below expectations due to production inefficiencies. Management has issued a cautious outlook for Q3 2025, anticipating temporary but higher-than-normal under-absorption effects from a prolonged maintenance stop, continued currency headwinds, and sustained market weakness. This is counterbalanced by a strong balance sheet, evidenced by a net cash position of SEK 33 million, which provides the financial stability to navigate the near-term challenges and continue strategic investments.

Key Decisions for Investors

• Investors should anticipate continued near-term pressure on the stock, as the company has explicitly guided for a seasonally weaker Q3 impacted by extended maintenance, significant currency headwinds, and cost under-absorption.
• Monitor order intake and backlog developments in the high-margin Medical, Nuclear, and Oil & Gas segments, as their performance is critical to offsetting the cyclical downturn in the Industrial and Chemical & Petrochemical divisions.
• For value-oriented investors, the sharp price drop to near its 52-week low, coupled with an attractive P/E ratio of 12.41 and a strong net cash position, may represent a compelling entry point, assuming a recovery post the guided Q3 trough.
• Closely track management's progress on resolving the production efficiency issues within the Strip division, as a successful turnaround in this segment is a key potential catalyst for margin improvement in the latter half of the year.